BCOR and TP53-Mutated Conventional and Dedifferentiated Chondrosarcoma: A Clinicopathologic Study

被引：0

作者：

Cerrillo, Diego Montoya ^{[1
]}

Beshah, Fireneh ^{[2
]}

Torres, Jaylou Velez ^{[3
]}

Montgomery, Elizabeth ^{[3
]}

Rosenberg, Andrew ^{[2
]}

机构：

[1] Univ Miami Hosp, Jackson Mem Hosp, Miami, FL USA

[2] Univ Miami Hlth Syst, Miami, FL USA

[3] Univ Miami, Miller Sch Med, Miami, FL 33136 USA

来源：

LABORATORY INVESTIGATION | 2024年 / 104卷 / 03期

关键词：

D O I：

暂无

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

引用

页码：S67 / S68

页数：2

共 50 条

[21] Somatic Mutations in TP53 Identified in T-Cells of Patients with TP53-mutated AML
Issa, Ghayas C.
Bidikian, Aram
Ayoub, Edward
Wang, Feng
Mohanty, Vakul
Leighton, Jake
Wu, Xiaogang
Patsilevas, Tallie
Alaniz, Zoe
Zarka, Jabra
Kanagal-Shamanna, Rashmi
Daver, Naval
Futreal, Andy
Konopleva, Marina
Navin, Nicholas
Zhang, Jianhua
Chen, Ken
Andreeff, Michael
BLOOD, 2022, 140 : 6267 - 6269
[22] TP53 Combined Phenotype Score Is Associated with the Clinical Outcome of TP53-Mutated Myelodysplastic Syndromes
Yabe, Mariko
Omarbekova, Aidana Z.
Hsu, Meier
May, Hannah
Arcila, Maria E.
Liu, Ying
Dogan, Ahmet
Brunner, Andrew M.
Nardi, Valentina
Hasserjian, Robert P.
Klimek, Virginia M.
CANCERS, 2021, 13 (21)
[23] Predicted Functional Consequences of TP53 Alterations and Prognosis in TP53-Mutated Mantle Cell Lymphoma
Uppal, Manik
Joffe, Erel
Bantilan, Kurt S.
Salles, Gilles
Soumerai, Jacob
Zelenetz, Andrew D.
Kumar, Anita
BLOOD, 2023, 142
[24] Are We Moving the Needle for Patients with TP53-Mutated Acute Myeloid Leukemia?
Shallis, Rory M.
Bewersdorf, Jan P.
Stahl, Maximilian F.
Halene, Stephanie
Zeidan, Amer M.
CANCERS, 2022, 14 (10)
[25] Treatment patterns and outcomes of patients with TP53-mutated chronic lymphocytic leukemia
Hwang, Steven
Wang, Yucai
Rabe, Kari
Williams-Watley, Marquise
Kenderian, Saad
Muchtar, Eli
Hampel, Paul
Kay, Neil
Koehler, Amber
Behnken, Amy
Leis, Jose
Braggio, Esteban
Shi, Min
Viswanatha, David
Van Dyke, Daniel
Slager, Susan
Parikh, Sameer
He, Rong
Ding, Wei
LEUKEMIA & LYMPHOMA, 2023, 64 : S84 - S85
[26] Niclosamide combined to Azacitidine to target TP53-mutated MDS/AML cells
Maslah, Nabih
Rety, Salome
Bonnamy, Melina
Aguinaga, Lorea
Huynh, Tony
Parietti, Veronique
Giraudier, Stephane
Fenaux, Pierre
Cassinat, Bruno
LEUKEMIA, 2024, 38 (07) : 1630 - 1633
[27] TP53-Mutated Myelodysplastic Syndrome: A Diagnostic Approach in Different Clinical Settings
Kaseb, Hatem
Crane, Genevieve
Gibson, Jane
GENETIC TESTING AND MOLECULAR BIOMARKERS, 2024, 28 (06) : 219 - 222
[28] Spindle assembly checkpoint as a therapeutic target for TP53-mutated myeloid neoplasms
Arsana, Arini
Huang, Huixing
Al-Kali, Arief
Shah, Mithun
CANCER RESEARCH, 2024, 84 (06)
[29] Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes
Montalban-Bravo, Guillermo
Kanagal-Shamanna, Rashmi
Benton, Christopher B.
Class, Caleb A.
Chien, Kelly S.
Sasaki, Koji
Naqvi, Kiran
Alvarado, Yesid
Kadia, Tapan M.
Ravandi, Farhad
Daver, Naval
Takahashi, Koichi
Jabbour, Elias
Borthakur, Gautham
Pemmaraju, Naveen
Konopleva, Marina
Soltysiak, Kelly A.
Pierce, Sherry R.
Bueso-Ramos, Carlos E.
Patel, Keyur P.
Kantarjian, Hagop
Garcia-Manero, Guillermo
BLOOD ADVANCES, 2020, 4 (03) : 482 - 495
[30] Establishment and Characterization of a TP53-Mutated Eyelid Sebaceous Carcinoma Cell Line
Gu, Xiang
Huang, Ziyue
Chen, Jie
Luo, Yingxiu
Ge, Shengfang
Jia, Renbing
Song, Xin
Chai, Peiwei
Xu, Shiqiong
Fan, Xianqun
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2023, 64 (15)

← 1 2 3 4 5 →